Aspirin Use to Prevent Cardiovascular Disease in Adults: Interpretation of U.S. Preventive Services Task Force Recommendations Statement
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. In April 2022, the U.S. Preventive Services Task Force (USPSTF) updated and published recommendations on aspirin use to prevent CVD based on the latest evidence-based research results. The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years and above. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one based on shared decision-making between clinicians and patients about the potential benefits and harms. This paper aims to interpret the latest recommendations in the context of China's actual situation, providing a reference on aspirin use to prevent CVD in China..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Zhongguo quanke yixue - 27(2024), 11, Seite 1277-1282 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
LI Mingyan, SHI Weili, DUAN Hongyan [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Cardiovascular diseases|aspirin|primary prevention|adult|guidebook |
|---|
| doi: |
10.12114/j.issn.1007-9572.2023.0848 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091482984 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091482984 | ||
| 003 | DE-627 | ||
| 005 | 20240412093720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.12114/j.issn.1007-9572.2023.0848 |2 doi | |
| 035 | |a (DE-627)DOAJ091482984 | ||
| 035 | |a (DE-599)DOAJe478aca6f6494c3a98d9eac69d02ce40 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 0 | |a LI Mingyan, SHI Weili, DUAN Hongyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aspirin Use to Prevent Cardiovascular Disease in Adults: Interpretation of U.S. Preventive Services Task Force Recommendations Statement |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Cardiovascular disease (CVD) is one of the leading causes of death worldwide. In April 2022, the U.S. Preventive Services Task Force (USPSTF) updated and published recommendations on aspirin use to prevent CVD based on the latest evidence-based research results. The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years and above. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one based on shared decision-making between clinicians and patients about the potential benefits and harms. This paper aims to interpret the latest recommendations in the context of China's actual situation, providing a reference on aspirin use to prevent CVD in China. | ||
| 650 | 4 | |a cardiovascular diseases|aspirin|primary prevention|adult|guidebook | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Zhongguo quanke yixue |d Chinese General Practice Publishing House Co., Ltd, 2024 |g 27(2024), 11, Seite 1277-1282 |w (DE-627)DOAJ090664779 |x 10079572 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2024 |g number:11 |g pages:1277-1282 |
| 856 | 4 | 0 | |u https://doi.org/10.12114/j.issn.1007-9572.2023.0848 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e478aca6f6494c3a98d9eac69d02ce40 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.chinagp.net/fileup/1007-9572/PDF/20230848.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1007-9572 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2024 |e 11 |h 1277-1282 | ||